MedTrace Logo

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

NCT03973918 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-10-31

Study results available
· View outcomes & findings →

Summary

The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.

Conditions

Interventions

DRUG

Encorafenib

450mg QD 28 day cycle

DRUG

Binimetinib

45mg BID 28 day cycle

BIOLOGICAL

Research Bloods

Baseline; pre-cycle 3; Pre-cycle 7; off Treatment

BIOLOGICAL

Tumor Tissue

at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Pfizer

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Karisa C Schreck, MD · ABTC

  • Stuart A Grossman, MD · ABTC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-29
Primary Completion
2022-04-30
Completion
2023-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973918 on ClinicalTrials.gov